Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RCAT cells
- Development stage
- Unknown
- Lead developer
- Henan Cancer Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
RCAT cells (Renal Cancer-Associated T cells) are an autologous adoptive cell therapy developed by Henan Cancer Hospital for the treatment of advanced renal cell carcinoma (RCC). The therapy involves the isolation of T cells from the patient, which are then expanded and activated ex vivo to specifically recognize and target renal cancer-associated antigens. Once re-infused into the patient, these sensitized T cells are designed to infiltrate the tumor microenvironment and exert cytotoxic effects against malignant cells. This personalized immunotherapy approach aims to overcome the immune evasion mechanisms of RCC by providing a robust population of tumor-reactive effector cells.
- Other names
- Autologous Renal Cancer-Associated T cellsRenal Cancer-Associated T cells
Beyond the preview
Go deeper on RCAT cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RCAT cells.